Alendronate for 6 or 12 mo following denosumab discontinuation in women with postmenopausal osteoporosis: a prospective observational study
Authors' conclusion
In conclusion, alendronate did not consistently attenuate BMD loss and BTM rebound after denosumab discontinuation in women with PMO, with 6 months being as effective as 12 months of treatment.
Study context
- Population
- Women with postmenopausal osteoporosis (PMO) treated with denosumab (Dmab) 60 mg every 6 months who achieved osteopenia at lumbar spine (LS) and femoral neck (FN); Alendronate (ALN) started 6 months after last Dmab injection; median age 67 yearscompleted the study
- Participants
- 80 women
- Exposure
- ALN 70 mg weekly for 6 months then 6 months without therapy vs ALN for 12 months after Dmab discontinuation
- Group 1n = 39
- Group 2n = 41
- Outcome
- Percent change in LS-BMD from baseline
- Follow-up
- Month 12
Methodological details12-month
- 12-month
Main finding
As reported in the abstract
Percent change in LS-BMD
Group 1
−6.8%
Group 2
−5.0%
P = 0.50
- LS-BMD change, overall cohort
- −5.9% (8.2%), p < 0.001
Observational data: associations, not effects.
Further findings
FN-BMD change · month 12
- FN-BMD decreased, overall cohort
- −3.5%, p < 0.001
- Similar decrease in both groups
Bone turnover markers (BTM) (P1NP, CTX, TRACP-5b) · month 12
- P1NP, CTX and tartrate-resistant acid phosphatase isoform 5b increased significantly
- P1NP and CTX significantly higher in Group 1 at month 12
Safety
- Patients with multiple vertebral fractures
- One patient (1.25%)
Original publication
Alendronate for 6 or 12 mo following denosumab discontinuation in women with postmenopausal osteoporosis: a prospective observational study. J Bone Miner Res. Published 23 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →